Evidence map›Paper›PMID 33772730›Full record

ArticleInternational journal of hematology2021

Newly diagnosed follicular lymphoma during pembrolizumab treatment for lung cancer.

Yoshiaki Marumo, Shigeru Kusumoto, Ayako Masaki, Takahiro Nakashima, Takaki Kikuchi, Fumiko Mori, Hirokazu Komatsu, Hiroshi Inagaki, Shinsuke Iida, Atsushi Inagaki

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yoshiaki MarumoNagoya City West Medical Center Hematology and Oncology, Nagoya, Japan.
Shigeru KusumotoDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan. skusumot@med.nagoya-cu.ac.jp.ORCID http://orcid.org/0000-0001-6546-1279
Ayako MasakiDepartment of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Takahiro NakashimaNagoya City West Medical Center Hematology and Oncology, Nagoya, Japan.
Takaki KikuchiNagoya City West Medical Center Hematology and Oncology, Nagoya, Japan.
Fumiko MoriNagoya City West Medical Center Hematology and Oncology, Nagoya, Japan.
Hirokazu KomatsuDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Hiroshi InagakiDepartment of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Shinsuke IidaDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Atsushi InagakiNagoya City West Medical Center Hematology and Oncology, Nagoya, Japan.
Nagoya City University · JPNagoya Medical Center · JPNagoya Memorial Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant lymphoma developing during anti-PD-1 antibody treatment is extremely rare. A 74-year-old female was admitted with left hypochondrial pain. She was diagnosed with squamous cell carcinoma of the right upper lobe of the lung, and had undergone surgery and postoperative chemotherapy three years prior. Needle biopsy of a mediastinal lymph node revealed recurrent lung cancer (LC). Pembrolizumab (PEM) monotherapy was started as salvage treatment. Although her lymphadenopathy improved, thrombocytopenia and splenomegaly developed during treatment with nine doses of PEM. Laboratory findings included anemia, increased lactate dehydrogenase, and soluble interleukin-2 receptor levels of 6379 U/mL. Flow cytometry of peripheral blood and bone marrow showed CD20

Indexed as

AgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsBiopsyFemaleHumansLung NeoplasmsLymph NodesLymphoma, FollicularNeoplasms, Second PrimaryPositron Emission Tomography Computed TomographyAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalpembrolizumabFollicular lymphomaImmune checkpoint inhibitorsLung cancerPembrolizumab

Identifiers

PMID33772730
OpenAlexW3141838921

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.